BridgeBio Pharma, Inc.
For the period ended Sep 30, 2025. Filed Oct 29, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Oct 29, 2025
BBIO$78.67+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Revenues: | ||||
| Net product revenue | $108,111 | $— | $216,351 | $— |
| License and services revenue | 8,311 | 2,732 | 125,441 | 216,020 |
| Royalty revenue | 4,278 | — | 6,106 | — |
| Total revenues, net | 120,700 | 2,732 | 347,898 | 216,020 |
| Operating costs and expenses: | ||||
| Cost of revenues: | ||||
| Cost of goods sold | 4,028 | — | 8,910 | — |
| Cost of license, services and royalty revenue | 2,535 | 598 | 3,945 | 1,794 |
| Total cost of revenues | 6,563 | 598 | 12,855 | 1,794 |
| Research and development | 112,874 | 120,444 | 335,536 | 376,111 |
| Selling, general and administrative | 137,621 | 68,819 | 373,140 | 194,149 |
| Restructuring, impairment and related charges | 8,841 | 4,621 | 10,216 | 10,912 |
| Total operating costs and expenses | 265,899 | 194,482 | 731,747 | 582,966 |
| Loss from operations | (145,199) | (191,750) | (383,849) | (366,946) |
| Other income (expense), net: | ||||
| Interest income | 6,239 | 3,296 | 15,522 | 12,566 |
| Interest expense | (11,739) | (23,061) | (41,467) | (69,469) |
| Noncash interest expense on deferred royalty obligations (1) | (36,410) | — | (86,460) | — |
| Gain on deconsolidation of subsidiaries | — | 52,027 | — | 178,321 |
| Loss on extinguishments of debt | — | — | (21,155) | (26,590) |
| Net loss from equity method investments | (15,834) | (6,563) | (51,579) | (14,488) |
| Other income, net | 16,461 | 1,797 | 31,240 | 10,648 |
| Total other income (expense), net | (41,283) | 27,496 | (153,899) | 90,988 |
| Loss before income taxes | (186,482) | (164,254) | (537,748) | (275,958) |
| Provision for (benefit from) income taxes | (1,545) | — | 555 | — |
| Net loss | (184,937) | (164,254) | (538,303) | (275,958) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 2,194 | 2,214 | 6,235 | 5,246 |
| Net loss attributable to common stockholders of BridgeBio | $(182,743) | $(162,040) | $(532,068) | $(270,712) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.95) | $(0.86) | $(2.79) | $(1.46) |
| Weighted-average shares used in computing net loss per share attributable to common stockholders of BridgeBio, basic and diluted | 191,854,152 | 188,510,372 | 190,845,133 | 184,947,173 |
(1)Including related party amounts of $(5,383) and $(5,560) for the three and nine months ended September 30, 2025, respectively (as described in Note 10).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.